clinical trial · NCT07220603
An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)
PepGen Inc·phase2·recruiting·n = 48
Myotonic Dystrophy 1PGN-EDODM1
brief summary
The purpose of this study is to learn about the long-term safety and tolerability of PGN-EDODM1 in participants with myotonic dystrophy type 1 (DM1) who have completed a prior study with PGN-EDODM1.
started
Dec 23, 2025
primary completion
Jan 1, 2029
completion
Jan 1, 2029
last updated
Mar 30, 2026
official title
An Open-Label Extension Study Evaluating Safety and Pharmacokinetics in Participants With Myotonic Dystrophy Type 1 (FREEDOM-OLE)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol